Amyloid clearance tracked with far less tau in one Alzheimer’s brain
A rare postmortem examination of an Alzheimer’s disease brain has exposed a striking internal split: regions where amyloid plaques had been largely removed showed little tau accumulation, while neighboring areas that still held amyloid carried far more tau, inflammation, and tissue injury. The case offers unusually direct human evidence that plaque removal may do more than reduce a biomarker on a scan. It may also interrupt the chain of events that drives neuronal loss and memory decline.
The findings matter because Alzheimer’s biology has long been framed as a cascade. Beta-amyloid gathers outside neurons, tau builds inside them, and the two proteins together track with cognitive deterioration. Anti-amyloid drugs have already changed treatment, but the field has struggled to prove whether clearing plaques alters the later, more destructive tau phase in humans rather than only lowering amyloid burden.
This brain provided a rare opportunity to compare both processes side by side.
A patchwork of damage inside adjacent gyri and sulci
The man had developed mild cognitive impairment in his fifties and entered a clinical trial of aducanumab, receiving 30 doses over four and a half years. He died about four years after his last dose, more than a decade after symptom onset, and had requested brain donation before death. Tissue from the donated brain was examined at the Center for Neurodegenerative Disease Research.
The anatomy told a sharply uneven story. The ridges of the brain’s folded surface, the gyri, had lost most amyloid plaques and showed very little tau. Nearby grooves, the sulci, still contained substantial amyloid and displayed much higher tau burden, inflammation, and degeneration. Living scans had already suggested this mismatch, but autopsy tissue made the relationship visible at cellular resolution.
The contrast was not subtle. Regions that had responded to plaque removal looked biologically quieter; regions that had not remained active sites of injury.
What the brain tissue suggests about the amyloid-tau sequence
The case strengthens a biological model that has been suspected but hard to document in human tissue: amyloid removal may help prevent downstream tau spread, or at least limit the conditions that allow tau to accumulate. In practical terms, amyloid appears to be more than a passive deposit. It may create a local environment that permits tau aggregation, inflammation, and neurodegeneration to advance.
When plaques disappeared from a region, tau was largely absent there as well. Where plaques persisted, tau remained abundant. That pattern supports the idea that early and thorough plaque clearance could preserve brain tissue before the tau phase becomes entrenched. The result also aligns with a more aggressive therapeutic window, one in which intervention before extensive tau pathology may offer the greatest chance of preserving cognition.
One brain region looked protected; the next was still deteriorating.
Why this single case still matters clinically
The report is only one person, and no single autopsy can establish causation. Still, rare human neuropathology carries particular weight because it shows what happened inside the brain after years of therapy, not only what happened on short-term clinical trials. Most Alzheimer’s drug studies follow patients for roughly 18 months. That interval may be too short to capture delayed structural benefits if amyloid removal needs years to translate into meaningful protection against tau spread and tissue loss.
The case also fits the current generation of amyloid-targeting drugs, including donanemab and lecanemab, which work through mechanisms similar to the therapy used here. Aducanumab was the first drug of this class to receive accelerated FDA approval, though it is no longer sold. The broader question now is whether deep plaque clearance with newer agents can change the disease trajectory enough to delay serious decline, especially when treatment begins before irreversible damage is established.
Early treatment may be the real inflection point
Alzheimer’s pathology can accumulate silently for years before memory problems appear. That long presymptomatic interval has become a central target for researchers who want to intervene before tau tangles spread widely through vulnerable networks.
Christopher A. Brown, the study’s first author, described the case as evidence that amyloid removal early in disease may help limit the changes that damage brain cells. David Wolk and Edward B. Lee framed the tissue findings as some of the clearest human evidence yet that anti-amyloid therapy may restrain tau and slow the brain changes tied to cognitive decline.
The biology makes sense. If amyloid seeds an environment that accelerates tau pathology, then removing amyloid before tau becomes established could interrupt a self-propagating process. Once tau deposition and neurodegeneration are widespread, the opportunity may narrow considerably. This is why preclinical disease and early symptomatic stages remain such a focus for therapeutic development.
What remains unknown after the autopsy
The study cannot define how much amyloid must be removed to protect the brain, whether the benefit depends on regional patterns of clearance, or whether plaque removal alone caused the difference in tau burden. It also cannot show how durable the effect is across larger groups of patients or how often this kind of gyri-sulci mismatch appears after anti-amyloid therapy.
Those gaps leave several practical questions for future trials and neuropathology studies. Do some brain regions respond better to amyloid-clearing treatment than others because of vascular factors, drug delivery, or local tissue biology? Does earlier treatment consistently reduce later tau accumulation? And can biomarker-imaging strategies identify patients most likely to gain long-term protection from plaque removal?
The answer will require more brains, longer follow-up, and trials designed to outlast the short observation windows that dominate current drug development.
For now, this case offers a rare view of Alzheimer’s disease after treatment has done its work. In one part of the brain, amyloid was gone and tau stayed low. A few millimeters away, both proteins remained, along with the damage they leave behind.